| abstract |
The invention relates to an in vivo functional ligands (IFLs) including a single-chain variable fragment (scFv) domain, a fragment crystalIizable (Fc) domain, and a hinge domain joining the scFv and Fc domains. The IFLs specifically bind target receptors and are capable of triggering antibody-dependent cell cytotoxicity (ADCC), antibody-dependent cell phagocytosis (ADCP) and complement-dependent cytotoxicity (CDC), as well as cytokine stimulation. The IFLs may be joined to a chimeric antigen receptor via a self-cleaving peptide. The IFLs may be expressed in immune cells, such as a natural killer cell or a T lymphocyte. Vectors, host cells, and methods of making IFLs are also described. |